A large number of thiometallate anions, MOxS4-xn-, and some of the seleno a
nalogues, are known in which M is a transition metal in a high oxidation st
ate. They are characterised by their strong colours arising from low energy
S(Se)-->M charge transfer transitions, by unusual redox properties and by
their ability to act as ligands to produce a wide range of heterometal comp
lexes. This review outlines some of these properties associated with the th
iometallate anions of molybdenum(VI). These anions are prepared by passing
H2S through an alkaline molybdate solution, giving a sequential replacement
of O atoms by S and ultimately MoS42- (TTM) as product. The thiomolybdates
, particularly TTM, have been the most intensively studied because of their
ease of preparation, their relatively greater thermal and hydrolytic stabi
lities and their biological roles. Unusual redox changes which involve inte
rnal electron transfer have been shown by reaction with organic disulfides
and with Cu-II. I, the latter case insoluble polymeric products are readily
formed which, from EPR and EXAFS studies, involve S-bridged reduced Cu and
Mo centres. Reaction of TTM with Cu-I, on the other hand, produces a range
of complexes in which from 1 to 6 Cu ions add across the tetrahedral faces
of TTM with no redox changes. Further Cu-I ions can be added to the [Cu-6(
MoS4)] moiety to produce cluster ions. This illustrates the ability of the
thiometallates to act as building blocks for a very wide range of heteromet
al complexes ranging from simple linear ions to complex clusters, a prime e
xample of the latter being the FeMo cofactor of the enzyme nitrogenase. TTM
was identified sometime ago as the reactive intermediate in the Mo-induced
Cu-deficiency that afflicts ruminants with serious consequences. Subsequen
tly TTM, as its ammonium salt, has been successfully used in removing the e
xcess Cu and then controlling the Cu levels of patients of Wilson's disease
. It appears to act by blocking the intestinal absorption of Cu and by conv
erting Cu into a metabolically inert form, and in these respects is differe
nt to the mode of action of chelating agents which can be used for treating
this disease.